

Reproducibility of arterial spin labeling and blood-oxygen level dependent measures of cerebrovascular reactivity using a controlled cerebrovascular challenge

J. D. Winter¹, J. Leung¹, M. Shroff^{2,3}, and A. Kassner^{1,3}

¹Physiology and Experimental Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada, ²Diagnostic Imaging, The Hospital for Sick Children, Toronto, Ontario, Canada, ³Medical Imaging, University of Toronto, Toronto, Ontario, Canada

Introduction: Cerebrovascular reactivity (CVR), the cerebral blood flow (CBF) response to a vasoactive stimulus, provides an additional tool for the clinical assessment of cerebrovascular disease¹. MRI acquisition of regional CVR images is typically performed using relative blood-oxygen level dependent (BOLD) signal changes or arterial spin labeling (ASL) measures of CBF in response to experimental manipulation of CO₂. CVR imaging with BOLD provides an indirect measure of CBF changes that is dependent on multiple factors. Advantages of BOLD imaging include improved SNR (compared with ASL) and wide availability of BOLD sequences. Furthermore, the precise control of end-tidal PCO₂ (PETCO₂) via a computer-controlled, model-driven end-tidal prospective targeting (MPET) system can be used to improve the accuracy and reliability of BOLD-CVR imaging². Clinical utility of ASL-based CVR measures may be improved with higher magnetic field strength, novel acquisition strategies, and use of a controlled cerebrovascular challenge. We hypothesized that ASL measures of CBF performed using a modified Look-Locker (LL) acquisition strategy at 3.0 T, in combination with a controlled CO₂ stimulus, would provide ASL-CVR values with similar reproducibility to BOLD-CVR values.

Methods: Four healthy adult subjects (21 - 29 years old, 2 males, 2 females) were imaged on a 3.0 T Philips MRI scanner. PETCO₂ and PETO₂ targets were achieved using a MPET (RespirAct™, Thornhill Research Inc., Toronto, Canada)³, which maintains PETCO₂ and PETO₂ levels in close agreement with arterial blood gas values⁴. We assessed long-term reproducibility by collecting test-retest BOLD-CVR and test-retest ASL-CVR measurements performed on two separate days, 2 weeks apart. BOLD-CVR measurements were acquired during four square-wave cycles of hypercapnia (PETCO₂ = 44 mmHg for 60 s) and normocapnia (PETCO₂ = 37 mmHg for 60 s). BOLD imaging parameters included: TE = 30 ms, TR = 2 s, FOV = 220 mm, matrix size = 64 × 64, SENSE = 1.8, slices = 25, slice thickness = 5 mm, volumes = 270, and scan time = 9 min. Perfusion-weighted (ΔM) ASL images were collected using a pulsed STAR labeling method (150 mm plane 30 mm inferior to the imaging slab) combined with a LL readout that sampled eight label delay times from 650 ms to 3450 ms. Imaging parameters included: FOV = 220 mm, matrix 64 × 64, number of slices = 9, slice thickness = 5 mm, SENSE = 2.3, temporal resolution = 8 s, and scan time = 9 min. Baseline CBF measurements were collected (30 averages) without PETCO₂ control; whereas, ASL-CVR measurements (68 averages) were collected during MPET square-wave cycling of PETCO₂, which was identical to the protocol used for BOLD-CVR imaging. Baseline CBF images were quantified by fitting the average ΔM images to the modified kinetic model described by Gunther *et al.*⁵. ASL-CVR was quantified by fitting average ΔM images collected at hyper- and normocapnia to the model separately. ASL-CVR was expressed as the percent CBF change per unit PETCO₂. To separate gray matter (GM) and white matter (WM) regions, we segmented high-resolution 3D anatomical images. Baseline CBF, BOLD-CVR and ASL-CVR images were then transformed to the anatomical images to extract mean GM and WM values. Reproducibility was assessed using the between-day coefficient of variation (CV).

Results: Test-retest images from a representative subject are provided for baseline ASL CBF (Figure 1), BOLD-CVR (Figure 2) and ASL-CVR (Figure 3). Mean baseline ASL CBF measures exhibited good between-day reproducibility for both the GM and WM regions (CV < 8 %, Table 1). Between-day BOLD-CVR measures in GM and WM had a CV < 19 % (Table 1), which was similar to the reproducibility of the ASL measures of the CBF reactivity to CO₂ (CV < 17 %).

Discussion: In this study, we demonstrated the feasibility of generating quantitative CVR images with an LL ASL approach in combination with MPET delivery of precise PETCO₂ transitions. By targeting specific PETCO₂ levels, ΔM images can be separately averaged at low and high CO₂ levels to improve the SNR for the perfusion model fit. The % CBF reactivity to CO₂ in this study (6.5 % CBF / mmHg) was greater than a previous report using ASL at single inversion time of 1.7 s (4 % CBF / mmHg)⁶, which may, in part, be attributed to the use of a LL strategy that mitigates the influence of hypercapnia-induced transit time changes⁷. Poor ASL-CVR image quality and presence of negative values may be attributed to degraded ASL SNR in WM⁸. In terms of long-term reproducibility, ASL-CVR was similar to BOLD-CVR based on between-day CVs and these values were superior to a previous report using a 5 % fixed CO₂ gas challenge (CV > 40 %)⁹.

References: 1. Mandell DM, *et al.*, Stroke, **39**:2021-8, (2008); 2. Prisman E, *et al.*, JMRI, **27**:185-91, (2008). 3. Slessarev M, *et al.*, J Physiol., **581**:1207-19, (2007); 4. Ito S, *et al.*, J Physiol., **586**:3675-82, (2008); 5. Gunther M, *et al.*, MRM, **46**:974-84 (2001); 6. St. Lawrence K, *et al.*, JMRI, **15**:628-35 (2002). 7. Bolar DS, *et al.*, ISMRM, **716**, (2004). 8. Van Geldern P, *et al.*, MRM, **59**:788-95 (2008). 9. Leontiev O, *et al.*, Neuroimage, **35**:175-84 (2007).




Figure 1. Representative test (left) and retest (right) ASL images of CBF collected at baseline PETCO₂ levels.




Figure 2. Representative test (left) and retest (right) BOLD-CVR images collected during square-wave PETCO₂ changes.




Figure 3. Representative test (left) and retest (right) ASL-CVR images collected during square-wave PETCO₂ changes.

Region	Baseline ASL CBF (ml/100g/min)			BOLD-CVR (% MR signal /mmHg)			ASL CVR (% CBF / mmHg)		
	Trial 1 Mean	Trial 2 Mean	CV (%)	Trial 1 Mean	Trial 2 Mean	CV (%)	Trial 1 Mean	Trial 2 Mean	CV (%)
GM	34.2 ± 3.8	34.4 ± 5.2	7.9 ± 2.4	0.266 ± 0.032	0.258 ± 0.018	16.5 ± 5.4	7.1 ± 1.0	6.5 ± 0.8	13.9 ± 6.8
WM	25.5 ± 3.3	27.2 ± 3.9	7.1 ± 3.8	0.188 ± 0.022	0.183 ± 0.014	18.4 ± 5.8	6.4 ± 1.0	5.9 ± 0.5	16.3 ± 7.4

Table 1. N = 4. Test-retest baseline CBF, BOLD-CVR and ASL CVR values (mean ± SEM); coefficient of variation (CV), (mean ± SEM);